GLP-1s Hit 8% of US Prescriptions in March 2026
GLP-1 receptor agonists made up nearly 8 of every 100 US prescriptions filled in March 2026, with first-time obesity prescribing up 21.7% over the prior quarter.
May 8, 2026 · 2 min read
GLP-1 receptor agonists accounted for nearly 8 of every 100 prescriptions filled in the United States in March 2026, a milestone in a class of drugs that barely registered five years ago. The data, reported this week from a large-scale prescription-claims dataset, shows the growth is now driven almost entirely by anti-obesity prescribing rather than diabetes — the opposite of the pattern when these drugs first scaled.
What happened
Between December 2025 and March 2026, first-time anti-obesity prescriptions surged by 21.7%, while first-time anti-diabetic prescriptions actually fell 9.8% over the same window. The Q1 2026 quarter logged the largest quarter-over-quarter percentage-point gain since Truveta's GLP-1 tracking began.
The dataset attributes the inflection to several converging accelerants: updated obesity care guidelines, increased direct-to-consumer marketing, broader (if uneven) insurance coverage, and the late-2025 FDA approvals of oral semaglutide for obesity and other oral entrants. The shift is being felt downstream — pharmacy operations, manufacturer capacity, and benefit-plan budgets are all repricing around higher steady-state utilization.
Why it matters
Eight percent of all US prescriptions is a massive footprint for one drug class. To put it in scale, GLP-1s are now claiming a share of total scripts comparable to or exceeding many entire therapeutic categories. This has three near-term implications worth tracking.
First, the obesity-vs-diabetes split is now decisively obesity-led. That changes how plans, regulators, and the FDA treat the class — anti-obesity drugs face different coverage politics than diabetes therapeutics, and the Medicare GLP-1 Bridge launching July 1 is the first federal acknowledgment of this shift.
Second, the surge in oral GLP-1s (Rybelsus for diabetes, oral semaglutide for obesity, Lilly's orforglipron now FDA-approved) is reshaping who gets prescribed what. Pills are easier for primary care to start than weekly injections, which broadens the prescribing base meaningfully.
Third, the volume math is straining manufacturing. Even with brand expansions, brand-pen supply has been a persistent constraint, which has fed continued demand for compounded products despite tightening FDA enforcement. Our compounded semaglutide guide covers what the regulatory tightening looks like in practice.
What to watch
Several pieces of incoming data will sharpen the picture. Q2 2026 prescription volumes will indicate whether the Q1 inflection holds or reflects a one-time pull-forward (e.g., from new approvals). Manufacturer earnings due over the next month will give the supply-side counter-signal. And the Medicare Bridge launch on July 1 will measurably alter the Medicare-eligible slice of the prescription pie — Truveta's next quarterly readout will be the first to capture it.
For comparison context on how individual peptides are landing in the prescription mix, our tirzepatide vs semaglutide cluster covers the head-to-head data driving switching patterns inside the class.
Sources
Sources